{"commentary":{"count":11,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":5,"youtube":3,"podcast":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03556839\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"BEATcc","nct_id":"NCT03556839","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=beatcc-nct03556839. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"BEATcc","arms":[{"description":"Cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2+ bevacizumab 15mg/kg i.v D1 Q3W. Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologic therapy, namely bevacizumab, upon investigator discussion.","label":"Arm A","type":"ACTIVE_COMPARATOR"},{"description":"cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2 + bevacizumab 15mg/kg + atezolizumab 1200mg i.v, D1 Q3W.Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologics therapy, namely bevacizumab plus atezolizumab, upon investigator discussion.","label":"Arm B","type":"EXPERIMENTAL"}],"collaborators":["ARCAGY/ GINECO GROUP","Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies","MaNGO","NSGO","Japanese Gynecologic Oncology Group","Gynecologic Oncology Group Foundation","AGO Study Group","Apices Soluciones S.L.","Hoffmann-La Roche"],"completion_date":{"date":"2025-08-31","type":"ACTUAL"},"conditions":["Carcinoma of the Cervix, Stage IVB"],"enrollment":{"count":410,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Bevacizumab","type":"DRUG"},{"name":"Cisplatin/Carboplatin","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"}],"last_update":"2026-04-21","lead_sponsor":"Grupo Español de Investigación en Cáncer de Ovario","official_title":"A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-08-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival","timeFrame":"48 months"},{"measure":"Overall survival","timeFrame":"48 months"}],"references":[{"citation":"Takekuma M, Nishio S, Yamaguchi S, Yunokawa M, Nishio H, Nishino K, Kurosaki A, Minobe S, Villacampa G, Oaknin A, Okamoto A. Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc. J Gynecol Oncol. 2025 Nov;36(6):e116. doi: 10.3802/jgo.2025.36.e116. Epub 2025 May 19.","pmid":"40968753","type":"DERIVED"},{"citation":"Oaknin A, Gladieff L, Martinez-Garcia J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Farinas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcon J, Follana P, Romero I, Lebreton C, Perez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10-GEICO 68-C-JGOG1084-GOG-3030 Investigators. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1.","pmid":"38048793","type":"DERIVED"},{"citation":"Grau JF, Farinas-Madrid L, Oaknin A. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030). Int J Gynecol Cancer. 2020 Jan;30(1):139-143. doi: 10.1136/ijgc-2019-000880. Epub 2019 Oct 23.","pmid":"31645423","type":"DERIVED"}],"start_date":{"date":"2018-09-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix","url":"https://clinicaltrials.gov/study/NCT03556839"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/beatcc-nct03556839"}